Sanofi (EPA:SAN) has been given a €82.00 ($96.47) target price by research analysts at Goldman Sachs Group, Inc. (The) in a research report issued to clients and investors on Friday, November 3rd. The firm presently has a “neutral” rating on the stock. Goldman Sachs Group, Inc. (The)’s price objective would indicate a potential upside of 6.90% from the stock’s previous close.
SAN has been the topic of several other research reports. J P Morgan Chase & Co set a €90.00 ($105.88) price target on Sanofi and gave the company a “neutral” rating in a research note on Tuesday, August 1st. S&P Global set a €90.00 ($105.88) target price on Sanofi and gave the company a “neutral” rating in a research report on Monday, July 31st. Sanford C. Bernstein set a €90.00 ($105.88) target price on Sanofi and gave the company a “neutral” rating in a research report on Monday, July 31st. Jefferies Group LLC set a €87.00 ($102.35) price objective on Sanofi and gave the stock a “neutral” rating in a report on Thursday, August 24th. Finally, BNP Paribas set a €85.00 ($100.00) price objective on Sanofi and gave the stock a “neutral” rating in a report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of €87.24 ($102.63).
Shares of Sanofi (EPA SAN) traded up €0.27 ($0.32) on Friday, reaching €76.71 ($90.25). The company’s stock had a trading volume of 2,120,000 shares, compared to its average volume of 1,940,000. Sanofi has a 52-week low of €73.39 ($86.34) and a 52-week high of €92.97 ($109.38).
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with our FREE daily email newsletter.